GlycoMimetics GLYC Stock
GlycoMimetics Price Chart
GlycoMimetics GLYC Financial and Trading Overview
| GlycoMimetics stock price | 1.82 USD |
| Previous Close | 1.76 USD |
| Open | 1.84 USD |
| Bid | 0 USD x 1400 |
| Ask | 0 USD x 1800 |
| Day's Range | 1.73 - 1.93 USD |
| 52 Week Range | 0.53 - 4.16 USD |
| Volume | 504.95K USD |
| Avg. Volume | 286.5K USD |
| Market Cap | 122.71M USD |
| Beta (5Y Monthly) | 2.095422 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.58 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.5 USD |
GLYC Valuation Measures
| Enterprise Value | 48.72M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.5131578 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1636.1238 |
| Price/Book (mrq) | 1.9731405 |
| Enterprise Value/Revenue | 649.624 |
| Enterprise Value/EBITDA | -1.12 |
Trading Information
GlycoMimetics Stock Price History
| Beta (5Y Monthly) | 2.095422 |
| 52-Week Change | 208.06% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 4.16 USD |
| 52 Week Low | 0.53 USD |
| 50-Day Moving Average | 1.67 USD |
| 200-Day Moving Average | 1.67 USD |
GLYC Share Statistics
| Avg. Volume (3 month) | 286.5K USD |
| Avg. Daily Volume (10-Days) | 274.89K USD |
| Shares Outstanding | 64.25M |
| Float | 39.5M |
| Short Ratio | 4.08 |
| % Held by Insiders | 2.62% |
| % Held by Institutions | 54.46% |
| Shares Short | 1.42M |
| Short % of Float | 3.18% |
| Short % of Shares Outstanding | 2.20% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -58245.63% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -36.31% |
| Return on Equity (ttm) | -65.11% |
Income Statement
| Revenue (ttm) | 75K USD |
| Revenue Per Share (ttm) | 0.001 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 75K USD |
| EBITDA | -43492552 USD |
| Net Income Avi to Common (ttm) | -42395112 USD |
| Diluted EPS (ttm) | -0.75 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 65M USD |
| Total Cash Per Share (mrq) | 1.01 USD |
| Total Debt (mrq) | 651.73K USD |
| Total Debt/Equity (mrq) | 1.05 USD |
| Current Ratio (mrq) | 10.102 |
| Book Value Per Share (mrq) | 0.968 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -44366204 USD |
| Levered Free Cash Flow (ttm) | -31311240 USD |
Profile of GlycoMimetics
| Country | United States |
| State | MD |
| City | Rockville |
| Address | 9708 Medical Center Drive |
| ZIP | 20850 |
| Phone | 240 243 1201 |
| Website | https://www.glycomimetics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 38 |
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Q&A For GlycoMimetics Stock
What is a current GLYC stock price?
GlycoMimetics GLYC stock price today per share is 1.82 USD.
How to purchase GlycoMimetics stock?
You can buy GLYC shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for GlycoMimetics?
The stock symbol or ticker of GlycoMimetics is GLYC.
Which industry does the GlycoMimetics company belong to?
The GlycoMimetics industry is Biotechnology.
How many shares does GlycoMimetics have in circulation?
The max supply of GlycoMimetics shares is 84.99M.
What is GlycoMimetics Price to Earnings Ratio (PE Ratio)?
GlycoMimetics PE Ratio is now.
What was GlycoMimetics earnings per share over the trailing 12 months (TTM)?
GlycoMimetics EPS is -0.58 USD over the trailing 12 months.
Which sector does the GlycoMimetics company belong to?
The GlycoMimetics sector is Healthcare.
GlycoMimetics GLYC included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 19659.36 USD — |
-1.62
|
— — | 19598.88 USD — | 19861.56 USD — | — - | — — |
- {{ link.label }} {{link}}